Ibrutinib is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It treats certain types of cancer. Some of the cancers treated are mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and chronic graft-versus-host disease.
Inlyta has been approved for use as a treatment for advanced renal cell carcinoma (RCC) in adults, either on its own or in conjunction with other medications
Inspra is a selective aldosterone receptor antagonist containing eplerenone that effectively treats heart failure after myocardial infarction and hypertension. This medication blocks aldosterone's harmful effects on the heart and blood vessels, providing cardiovascular protection and improved survival rates.
ISENTRESS (raltegravir) is a human immunodeficiency virus integrase strand transfer inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients 4 weeks of age and older.
Keppra is a prescription anticonvulsant medication containing levetiracetam that effectively controls various types of seizures in epilepsy patients. This medication helps reduce seizure frequency and severity, making it easier for patients to manage their daily activities safely.
